Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis
Hyunwoo Lee(Princess Alexandra Hospital), Douglas L. Arnold(McGill University), Robert A. Brown(Montreal Neurological Institute and Hospital), Sridar Narayanan(Montreal Neurological Institute and Hospital), Kunio Nakamura(Cleveland Clinic), Mark S. Freedman(University of Ottawa), Jacqueline Chen(Montreal Neurological Institute and Hospital), Harold Atkins(University of Ottawa)
Cited by 21
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|American Journal of Ophthalmology|2006|551